Oak Hill Bio Announces Formation of Board of Directors
Preeminent Life Science Leaders Join Board to Guide New Company Committed to Developing Life-Changing Medicines for Extremely Preterm Infants and Patients Suffering from Rare Autoimmune Diseases
“We are delighted to have assembled an outstanding Board of Directors comprised of preeminent life science leaders who share our commitment to build a world-class neonatology and rare disease therapeutics company,” said
“I am excited to join the Oak Hill team as they embark on launching a new powerhouse in neonatology and rare diseases and look forward to working with the truly exceptional Board and management team that has been assembled. Oak Hill has set forth an ambitious mission focused on addressing major unmet needs for very vulnerable patients,” said
The members of the Oak
Edwin Moses, Ph.D. has more than 25 years of experience as a chief executive and chair of numerous life science companies. Most recently, he was Chairman and then CEO of Ablynx. During his 14-year tenure at Ablynx, he led its rapid growth from a small research-focused organization to one of Europe’s most successful biotechnology companies that was listed on Euronext Brussels and NASDAQ until its acquisition by Sanofi in 2018 for $4.8 billion. Before that, Dr. Mosesled the growth, stock listing and eventual sale of pharmaceutical services company, Oxford Asymmetry International, as CEO and later Chairman. He is currently Chairman of Achilles Therapeutics Ltd., Avantium NV, and LabGenius Ltd. David Colpmanhas more than 30 years of biopharma business development and strategy experience, including as Head of Global Business Development at Shire Pharmaceuticals Plcwhere he drove growth through a series of strategic acquisitions, licensing and divestment programs. Mr. Colpmanhas also held senior business development roles with Novo Nordisk A/S, and GlaxoSmithKline Plc. Mr. Colpmancurrently serves on the boards of Orexo AB and HRA Pharma Ltd. Daniel Curran, M.D. is Head, Rare Genetics & Hematology Therapeutic Area Unit at Takeda Pharmaceutical Company Ltd. Previously, Dr. Curranserved as Head of Takeda’s Center for External Innovationwhere he focused on diversifying and transforming Takeda’s research and development pipeline. Prior to joining Takeda, Dr. Curranled the corporate development group at Millennium Pharmaceuticals. Dr. Currancurrently serves on the board of Xilio Therapeutics. Josh Distler, J.D. is President and Chief Financial Officer of Oak Hill Bio. He has extensive experience building and investing in biotechnology companies, having served as Head of Crossover and Quantitative Equity at Athanor Capital, COO of Global Private Investing for D. E. Shaw & Co., Chief Operating Officer at Attenuon, a cancer drug development firm and as a Director of Schrödinger, Inc. Ramy Farid, Ph.D. is President, Chief Executive Officer, and a member of the board of directors of Schrödinger, Inc. Since joining the company in 2002, he has advanced the company's computational platform and drug discovery portfolio while assuming positions of increasing responsibility before becoming CEO in 2017. Dr. Faridhas played a key role in implementing major strategic initiatives, including more than 40 research collaborations and joint ventures, and led the company through its initial public offering in 2020. Dr. Faridcurrently also serves on the boards of Ajax Therapeutics and ShouTi. Mark McHale, Ph.D. is Chief Scientific Officer of Oak Hill Bio. Most recently, Dr. McHaleco-founded Aslan Pharmaceuticalsand served as its Chief Development Officer and Head of R&D. He has also held leadership positions with AstraZeneca and SmithKline Beecham (now GlaxoSmithKline Plc.).
Stern Investor Relations